ddp4 inhibitors and glp 1 DPP4 degrade the GLP1 incretion, which leads to suppression of the dpp 4 glp 1 combination

More importantly, cardiovascular and renal outcome studies have demonstrated that GLP-1RAs and related multi-receptor agonists not only lower body weight and blood glucose but also significantly reduce the risk of major adverse cardiovascular events (MACE) and the worsening of renal function

Tirzepatide Tirzepatide is a gastric inhibitory polypeptide (GIP) analog and a GLP-1 receptor agonist

This is a textbook health scam designed to exploit those seeking quick fixes for serious health conditions

International Journal of Antimicrobial Agents , 25 , 404408

The short version is no, and we will explain why up top so the rest of this comparison makes sense